Bot Chart, page-12112

I do think this month BOT will go crazy in anticipation of FDA approval as buyers lock in their positions on a company that will soon go commercial, THIS year, on a blockbuster drug. So short answer is yes.

i follow pharma ASX companies closely, traditionally at this part of the FDA approval cycle we see >50% increases pre-approval from here, and sometimes much more.

Its the most exciting time of the entire FDA calendar which takes upwards of 6-10 years on many occasions.

I follow another company with Phase 3 readouts by this time next year, and during that time the increases are not as dramitic but even larger overall as its a year of climbing shareprice as buyers become aware, BOT can attest to that having been through this same part of the cycle making us the price we are today with huge gains. And I think BOT has a chance of doubling this month if us shareholders are lucky, and holders hold tight.

Good luck to all, cya in 50 days when BOT have a product ready and approved to be on the shelves of all American chemists, for a product that does not have competition and a huge demand!